Existing investors put another $30mm into Calistoga
Calistoga Pharmaceuticals (hematological cancers and inflammation) raised $30mm through its Series B round from existing backers Alta Partners, Amgen Ventures, Frazier Healthcare, and Three Arch Partners. To date, the company has raised over $56mm. The latest funds will go towards development of Calistoga's clinical-stage isoform-selective PI3K inhibitors.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.